Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drug Combination May Slow Male Breast Cancer Growth

10.07.2006
Medical oncologists across the nation want to know whether a certain drug combination can slow the progression of male breast cancer, a rare disease that often goes undiagnosed until it’s in an advanced stage.

Zeina Nahleh, MD, director of breast oncology in the University of Cincinnati’s (UC) division of hematology and oncology, is leading a national phase-2 clinical trial to test whether the drug anastrozole (Arimidex), currently approved by the Food and Drug Administration (FDA) for treating breast cancer in postmenopausal women, can effectively fight the same disease in men.

“If we’re going to make significant advances against the disease,” says Nahleh, “we need better male-specific treatment strategies.”

Previous research has shown that the female hormone estrogen promotes the growth of certain types of breast cancer. Anastrozole is one of a class of drugs, known as non-steroidal aromatase inhibitors, that block the tumor’s use of estrogen and slow its development.

By treating male breast cancer with a combination of anastrozole and a synthetic hormone called goserelin, Nahleh believes physicians may be able to stop the transition of the male hormone testosterone to the estrogen estradiol, significantly lowering the man’s overall estrogen levels and limiting breast tumor growth.

Goserelin is what is known as a gonadotropin-releasing hormone, which stops testosterone production in men and decreases estradiol in women. It already has FDA approval for the treatment of prostate cancer, endometriosis and advanced premenopausal and perimenopausal breast cancer.

“The biology of breast cancer is different in men and women, so identical treatment methods are not the best solution,” explains Nahleh. “We believe that anastrozole—when used in conjunction with a gonadotropin-releasing hormone injection—will lower the amount of male estrogen in the body, resulting in better control of the breast tumor.”

The trial, sponsored by the National Cancer Institute and Southwest Oncology Group, is the first to test this specific drug combination in men with advanced breast cancer.

“We’ve seen a 26 percent increase in the number of male breast cancer cases since 1973, but the disease is so rare that there’s been little research to determine the best ways to detect and treat the disease specifically in men,” explains Nahleh.

Current male breast cancer treatment methods are based on accepted approaches to the disease in women. Unlike female breast cancer, says Nahleh, the relationship between the estrogen receptor and overall survival in men is uncertain. In addition, mortality from the disease has not declined as it has in women.

Under Nahleh’s direction, researchers from 53 medical centers nationwide will test the drug combination on about 60 male patients—age 18 or older—who have recurrent or advanced breast cancer.

Patients will receive an anastrozole pill every day and a goserelin injection on the first day of 12, month-long cycles. Every two months researchers will collect serum samples to evaluate blood estrogen levels. They will also obtain CAT scan and X-ray images of the tumor to determine how the patient is responding.

After the treatment, Nahleh and her team will follow patients for three years to determine whether the approach is a sustainable option for managing male breast cancer.

The American Cancer Society estimates that more than 1,700 men will be diagnosed with breast cancer in 2006 and about 27 percent will die from the disease.

Amanda Harper | EurekAlert!
Further information:
http://www.uc.edu

More articles from Health and Medicine:

nachricht Investigators may unlock mystery of how staph cells dodge the body's immune system
22.09.2017 | Cedars-Sinai Medical Center

nachricht Monitoring the heart's mitochondria to predict cardiac arrest?
21.09.2017 | Boston Children's Hospital

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Rainbow colors reveal cell history: Uncovering β-cell heterogeneity

22.09.2017 | Life Sciences

Penn first in world to treat patient with new radiation technology

22.09.2017 | Medical Engineering

Calculating quietness

22.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>